검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Opdivo (Nivolumab, Nivolumab (Opdivo)) Bristol Myers Squibb·Anaplastic Large Cell Lymphoma, AL… ORR 100%·t½ 0.5 h |
|---|---|
Overview Program | Nivolumab (Opdivo) |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Anaplastic Large Cell Lymphoma, ALK-Posi |
Overview Indication | Solid Tumors |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev |
MoA Biomarker | biomarkers |
PK/PD Half-life | 0.5 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Use of low-dose immune checkpoint inhibitors in low- and middle-income countries: a national survey of oncologists and hematologists in Mexico.. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for multiple cancers but remain largely inaccessible in low- and middle-income countries (LMICs) due to high costs and limited availability. Pharmacokinetic and pharmacodynamic d… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT03267498 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Opdivo (Nivolumab, Nivolumab (Opdivo)) Bristol Myers Squibb·Anaplastic Large Cell Lymphoma, AL… ORR 100%·t½ 0.5 h |
|---|---|
Overview Program | Nivolumab (Opdivo) |
Overview Company | Bristol Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Anaplastic Large Cell Lymphoma, ALK-Posi |
Overview Indication | Solid Tumors |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic rev |
MoA Biomarker | biomarkers |
PK/PD Half-life | 0.5 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Use of low-dose immune checkpoint inhibitors in low- and middle-income countries: a national survey of oncologists and hematologists in Mexico.. Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for multiple cancers but remain largely inaccessible in low- and middle-income countries (LMICs) due to high costs and limited availability. Pharmacokinetic and pharmacodynamic d… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT03267498 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교